Published in Int J Nanomedicine on May 24, 2011
Controlled release strategies for bone, cartilage, and osteochondral engineering--Part II: challenges on the evolution from single to multiple bioactive factor delivery. Tissue Eng Part B Rev (2013) 0.90
Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J Drug Deliv (2011) 0.84
van der Waals force-induced loading of proangiogenic nanoparticles on microbubbles for enhanced neovascularization. Nanoscale (2015) 0.75
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Polymeric system for dual growth factor delivery. Nat Biotechnol (2001) 7.20
Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev (2003) 7.08
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 6.96
Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med (2000) 5.58
Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res (2000) 4.97
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem (1999) 3.76
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene (1999) 3.45
Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol (1999) 3.42
Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med (2003) 3.16
VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation (2000) 3.13
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest (1999) 2.86
Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res (2007) 2.49
Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res (2000) 2.41
Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol (1998) 2.18
Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull (2002) 2.02
Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation (1994) 1.98
Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol (2002) 1.95
Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation (1995) 1.92
Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett (1999) 1.62
Structure and ligand binding properties of human serum albumin. Dan Med Bull (1990) 1.60
Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation (1995) 1.51
Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm (2000) 1.33
FLASH links the CD95 signaling pathway to the cell nucleus and nuclear bodies. EMBO J (2007) 1.26
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res (1999) 1.26
Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol (1994) 1.22
Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation (1994) 1.21
Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. J Biomed Mater Res (2000) 1.18
Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res (2005) 1.15
Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm (2000) 1.13
Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg (1995) 1.08
Combination of injectable multiple growth factor-releasing scaffolds and cell therapy as an advanced modality to enhance tissue neovascularization. Arterioscler Thromb Vasc Biol (2010) 1.07
Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target (1993) 1.07
Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine (2010) 1.01
Drug delivery systems and routes of administration of peptide and protein drugs. Eur J Drug Metab Pharmacokinet (1990) 0.97
Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis (2007) 0.92
Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol (1995) 0.92
Preparation of sterically stabilized human serum albumin nanospheres using a novel Dextranox-MPEG crosslinking agent. Pharm Res (1994) 0.87
Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnol Prog (2009) 0.82
An international survey of drug information centers. Drug Inf J (1985) 0.77
Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells. J Biomed Biotechnol (2010) 0.77
Replication by human DNA polymerase-iota occurs by Hoogsteen base-pairing. Nature (2004) 3.57
Yeast Rad5 protein required for postreplication repair has a DNA helicase activity specific for replication fork regression. Mol Cell (2007) 3.51
Opposing effects of ubiquitin conjugation and SUMO modification of PCNA on replicational bypass of DNA lesions in Saccharomyces cerevisiae. Mol Cell Biol (2004) 2.49
Human DNA polymerase kappa encircles DNA: implications for mismatch extension and lesion bypass. Mol Cell (2007) 2.46
Structural basis of high-fidelity DNA synthesis by yeast DNA polymerase delta. Nat Struct Mol Biol (2009) 2.44
Requirement of RAD5 and MMS2 for postreplication repair of UV-damaged DNA in Saccharomyces cerevisiae. Mol Cell Biol (2002) 2.37
Rev1 employs a novel mechanism of DNA synthesis using a protein template. Science (2005) 2.37
Stimulation of DNA synthesis activity of human DNA polymerase kappa by PCNA. Mol Cell Biol (2002) 2.15
Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen. Proc Natl Acad Sci U S A (2006) 2.06
Yeast Rev1 protein is a G template-specific DNA polymerase. J Biol Chem (2002) 1.86
Ubiquitylation of yeast proliferating cell nuclear antigen and its implications for translesion DNA synthesis. Proc Natl Acad Sci U S A (2006) 1.86
Human DNA polymerase iota incorporates dCTP opposite template G via a G.C + Hoogsteen base pair. Structure (2005) 1.80
Structural basis for the suppression of skin cancers by DNA polymerase eta. Nature (2010) 1.73
Protein-template-directed synthesis across an acrolein-derived DNA adduct by yeast Rev1 DNA polymerase. Structure (2008) 1.72
Regulation of polymerase exchange between Poleta and Poldelta by monoubiquitination of PCNA and the movement of DNA polymerase holoenzyme. Proc Natl Acad Sci U S A (2008) 1.71
Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination. Proc Natl Acad Sci U S A (2008) 1.66
Efficient and error-free replication past a minor-groove DNA adduct by the sequential action of human DNA polymerases iota and kappa. Mol Cell Biol (2004) 1.64
Highly error-free role of DNA polymerase eta in the replicative bypass of UV-induced pyrimidine dimers in mouse and human cells. Proc Natl Acad Sci U S A (2009) 1.62
Complex formation with Rev1 enhances the proficiency of Saccharomyces cerevisiae DNA polymerase zeta for mismatch extension and for extension opposite from DNA lesions. Mol Cell Biol (2006) 1.61
Mms2-Ubc13-dependent and -independent roles of Rad5 ubiquitin ligase in postreplication repair and translesion DNA synthesis in Saccharomyces cerevisiae. Mol Cell Biol (2006) 1.61
Human DINB1-encoded DNA polymerase kappa is a promiscuous extender of mispaired primer termini. Proc Natl Acad Sci U S A (2002) 1.59
Hoogsteen base pair formation promotes synthesis opposite the 1,N6-ethenodeoxyadenosine lesion by human DNA polymerase iota. Nat Struct Mol Biol (2006) 1.58
Role of human DNA polymerase kappa as an extender in translesion synthesis. Proc Natl Acad Sci U S A (2002) 1.51
Pol31 and Pol32 subunits of yeast DNA polymerase δ are also essential subunits of DNA polymerase ζ. Proc Natl Acad Sci U S A (2012) 1.50
Yeast DNA polymerase zeta (zeta) is essential for error-free replication past thymine glycol. Genes Dev (2003) 1.48
Roles of PCNA-binding and ubiquitin-binding domains in human DNA polymerase eta in translesion DNA synthesis. Proc Natl Acad Sci U S A (2008) 1.47
Efficient and error-free replication past a minor-groove N2-guanine adduct by the sequential action of yeast Rev1 and DNA polymerase zeta. Mol Cell Biol (2004) 1.47
Mechanism of nucleotide incorporation opposite a thymine-thymine dimer by yeast DNA polymerase eta. Proc Natl Acad Sci U S A (2003) 1.45
Fiber-based tissue engineering: Progress, challenges, and opportunities. Biotechnol Adv (2012) 1.42
Requirement of RAD52 group genes for postreplication repair of UV-damaged DNA in Saccharomyces cerevisiae. Mol Cell Biol (2007) 1.42
Translesion synthesis past acrolein-derived DNA adduct, gamma -hydroxypropanodeoxyguanosine, by yeast and human DNA polymerase eta. J Biol Chem (2002) 1.40
Mutational specificity and genetic control of replicative bypass of an abasic site in yeast. Proc Natl Acad Sci U S A (2008) 1.39
Crystal structure of the catalytic core of human DNA polymerase kappa. Structure (2004) 1.35
Yeast and human translesion DNA synthesis polymerases: expression, purification, and biochemical characterization. Methods Enzymol (2006) 1.34
Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. Bone Marrow Res (2010) 1.34
Complex formation of yeast Rev1 and Rev7 proteins: a novel role for the polymerase-associated domain. Mol Cell Biol (2005) 1.33
An incoming nucleotide imposes an anti to syn conformational change on the templating purine in the human DNA polymerase-iota active site. Structure (2006) 1.31
Requirement of Watson-Crick hydrogen bonding for DNA synthesis by yeast DNA polymerase eta. Mol Cell Biol (2003) 1.27
Requirement of yeast RAD2, a homolog of human XPG gene, for efficient RNA polymerase II transcription. implications for Cockayne syndrome. Cell (2002) 1.27
Error-free replicative bypass of (6-4) photoproducts by DNA polymerase zeta in mouse and human cells. Genes Dev (2010) 1.26
Dpo4 is hindered in extending a G.T mismatch by a reverse wobble. Nat Struct Mol Biol (2004) 1.24
Yeast DNA polymerase zeta is an efficient extender of primer ends opposite from 7,8-dihydro-8-Oxoguanine and O6-methylguanine. Mol Cell Biol (2003) 1.22
The stalling of transcription at abasic sites is highly mutagenic. Mol Cell Biol (2003) 1.22
Evidence for a Watson-Crick hydrogen bonding requirement in DNA synthesis by human DNA polymerase kappa. Mol Cell Biol (2005) 1.19
Human DNA polymerase iota utilizes different nucleotide incorporation mechanisms dependent upon the template base. Mol Cell Biol (2004) 1.19
Electrospun scaffolds for tissue engineering of vascular grafts. Acta Biomater (2013) 1.17
A role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine. Mol Cell Biol (2007) 1.15
Yeast DNA polymerase eta makes functional contacts with the DNA minor groove only at the incoming nucleoside triphosphate. Proc Natl Acad Sci U S A (2003) 1.12
Structure of the human Rev1-DNA-dNTP ternary complex. J Mol Biol (2009) 1.12
Trf4 and Trf5 proteins of Saccharomyces cerevisiae exhibit poly(A) RNA polymerase activity but no DNA polymerase activity. Mol Cell Biol (2005) 1.12
Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices. Appl Microbiol Biotechnol (2010) 1.11
ELA1 and CUL3 are required along with ELC1 for RNA polymerase II polyubiquitylation and degradation in DNA-damaged yeast cells. Mol Cell Biol (2007) 1.09
Biochemical evidence for the requirement of Hoogsteen base pairing for replication by human DNA polymerase iota. Proc Natl Acad Sci U S A (2005) 1.09
Structure of human DNA polymerase kappa inserting dATP opposite an 8-OxoG DNA lesion. PLoS One (2009) 1.09
Requirement of yeast Rad1-Rad10 nuclease for the removal of 3'-blocked termini from DNA strand breaks induced by reactive oxygen species. Genes Dev (2004) 1.08
Replication past a trans-4-hydroxynonenal minor-groove adduct by the sequential action of human DNA polymerases iota and kappa. Mol Cell Biol (2006) 1.08
Yeast Rev1 protein promotes complex formation of DNA polymerase zeta with Pol32 subunit of DNA polymerase delta. Proc Natl Acad Sci U S A (2009) 1.07
Human DNA polymerase iota promotes replication through a ring-closed minor-groove adduct that adopts a syn conformation in DNA. Mol Cell Biol (2005) 1.06
Complex formation of yeast Rev1 with DNA polymerase eta. Mol Cell Biol (2007) 1.06
PCNA binding domains in all three subunits of yeast DNA polymerase δ modulate its function in DNA replication. Proc Natl Acad Sci U S A (2011) 1.06
Role of DNA damage-induced replication checkpoint in promoting lesion bypass by translesion synthesis in yeast. Genes Dev (2009) 1.06
Stimulation of 3'-->5' exonuclease and 3'-phosphodiesterase activities of yeast apn2 by proliferating cell nuclear antigen. Mol Cell Biol (2002) 1.06
Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Adv Drug Deliv Rev (2011) 1.06
Yeast RAD26, a homolog of the human CSB gene, functions independently of nucleotide excision repair and base excision repair in promoting transcription through damaged bases. Mol Cell Biol (2002) 1.06
Requirement of ELC1 for RNA polymerase II polyubiquitylation and degradation in response to DNA damage in Saccharomyces cerevisiae. Mol Cell Biol (2006) 1.05
Requirement of Rad5 for DNA polymerase zeta-dependent translesion synthesis in Saccharomyces cerevisiae. Genetics (2008) 1.05
Complex formation with damage recognition protein Rad14 is essential for Saccharomyces cerevisiae Rad1-Rad10 nuclease to perform its function in nucleotide excision repair in vivo. Mol Cell Biol (2006) 1.05
Mutations in the ubiquitin binding UBZ motif of DNA polymerase eta do not impair its function in translesion synthesis during replication. Mol Cell Biol (2007) 1.05
A mechanism for the exclusion of low-fidelity human Y-family DNA polymerases from base excision repair. Genes Dev (2003) 1.05
Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr (2011) 1.04
DNA synthesis across an abasic lesion by human DNA polymerase iota. Structure (2009) 1.04
Structural basis for cisplatin DNA damage tolerance by human polymerase η during cancer chemotherapy. Nat Struct Mol Biol (2012) 1.02
Error-free replicative bypass of thymine glycol by the combined action of DNA polymerases kappa and zeta in human cells. Proc Natl Acad Sci U S A (2010) 1.02
Structural insights into yeast DNA polymerase delta by small angle X-ray scattering. J Mol Biol (2009) 1.02
Complements and the wound healing cascade: an updated review. Plast Surg Int (2013) 1.01
The mechanism of nucleotide incorporation by human DNA polymerase eta differs from that of the yeast enzyme. Mol Cell Biol (2003) 1.01
Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomedicine (2010) 1.01
Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol (2013) 1.00
Human DNA polymerase kappa uses template-primer misalignment as a novel means for extending mispaired termini and for generating single-base deletions. Genes Dev (2003) 0.98
DNA polymerase eta lacking the ubiquitin-binding domain promotes replicative lesion bypass in humans cells. Proc Natl Acad Sci U S A (2010) 0.97
Human DNA polymerase kappa forms nonproductive complexes with matched primer termini but not with mismatched primer termini. Proc Natl Acad Sci U S A (2006) 0.97
Distinct mechanisms of cis-syn thymine dimer bypass by Dpo4 and DNA polymerase eta. Proc Natl Acad Sci U S A (2005) 0.97
Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials (2012) 0.97
A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials (2011) 0.97
A single domain in human DNA polymerase iota mediates interaction with PCNA: implications for translesion DNA synthesis. Mol Cell Biol (2005) 0.96
Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int J Nanomedicine (2013) 0.96
Topical application of complement C3 in collagen formulation increases early wound healing. J Dermatolog Treat (2011) 0.95
Replication across template T/U by human DNA polymerase-iota. Structure (2009) 0.94
Chemistry of fogs at Agra, India: influence of soil particulates and atmospheric gases. Environ Monit Assess (2007) 0.93
Accelerated wound healing with topical application of complement C5. Plast Reconstr Surg (2012) 0.93
Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Appl Microbiol Biotechnol (2008) 0.93
Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy. Regen Med (2009) 0.93
Shear-thinning nanocomposite hydrogels for the treatment of hemorrhage. ACS Nano (2014) 0.93
Structural basis for error-free replication of oxidatively damaged DNA by yeast DNA polymerase η. Structure (2010) 0.92
EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer (2009) 0.92
The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNA(Ang1+Vegf) nanoparticles. Biomaterials (2012) 0.91
Human DNA polymerase η is pre-aligned for dNTP binding and catalysis. J Mol Biol (2011) 0.91
Gradient static-strain stimulation in a microfluidic chip for 3D cellular alignment. Lab Chip (2014) 0.90